A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab

Author： Mitchell Paul  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.27, Iss.7, 2011-07, pp. : 1465-1475

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spontaneous anatomical improvement on OCT findings in patients with neovascular age‐related macular degeneration without anti‐VEGF treatment

By  

ACTA OPHTHALMOLOGICA, Vol. 94, Iss. S256, 2016-10 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Implementation studies of ranibizumab for neovascular age‐related macular degeneration

By  

ACTA OPHTHALMOLOGICA, Vol. 92, Iss. 1, 2014-02 ,pp. : 98-98

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison between Aflibercept, Ranibizumab intravitreal injection on Neovascular Age‐related macular degeneration patients

By  

ACTA OPHTHALMOLOGICA, Vol. 94, Iss. S256, 2016-10 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Visual outcomes in patients with neovascular age‐related macular degeneration

By  

ACTA OPHTHALMOLOGICA, Vol. 96, Iss. 2, 2018-03 ,pp. : e254-e254

John Wiley & Sons Inc

Access to resources Recommend Favorite

Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age‐related macular degeneration

By  

ACTA OPHTHALMOLOGICA, Vol. 96, Iss. 2, 2018-03 ,pp. : e201-e212

John Wiley & Sons Inc

Access to resources Recommend Favorite